Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/genetics.3.016
Confronting Vaccine Production, Efficacy, Safety, and Accessibility Challenges in Africa
Ahmed Adebowale Adedeji1,4,*, Einas Mohammed ElHabib2, Rasheed Omotayo Adeyemo3,4
- 1Department of Pharmacology and Toxicology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Rwanda
- 2Foresight Institute of Research and Translation, 93 KK 31, Gikondo, Rwanda
- 3Department of Medical Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Rwanda
- 4Future of Medicine, Science, Technology and Innovation Research Group, School of Medicine and Pharmacy, University of Rwanda, Rwanda
Corresponding Author
Ahmed Adebowale Adedeji, a.adedeji@ur.ac.rw
Received Date: June 03, 2024
Accepted Date: June 27, 2024
Adedeji AA, Elhabib EM, Adeyemo RO. Confronting Vaccine Production, Efficacy, Safety, and Accessibility Challenges in Africa. Arch Mol Biol Genet. 2024;3(1):20-23.
Copyright: © 2024 Adedeji AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
COVID-19 Clinical Outcomes and Vaccine Efficacy among Patients with Hematologic Malignancies
The coronavirus disease 2019 (COVID-19) pandemic places the treating hematologist in a quandary: how best to protect patients with hematologic malignancies from potentially deadly COVID-19 infection while also providing the best therapy for their disease and maximizing opportunities for cure. Cancer patients as a whole trend toward more severe infection and increased mortality from COVID-19 infection.
Cardiovascular Adverse Events after COVID-19 Vaccination
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a global pandemic by the World Health Organization in March 2020 and since then, it has caused huge economic and social turmoil worldwide [1]. In an attempt to reduce the spread across the United States (U.S.) and worldwide, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) of different vaccines (BNT-162b2, mRNA-1273, and Ad26.COV2. S).
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
Vaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths.
Change in Prevalence of Meningitis among Children with Febrile Seizure after the Pentavalent Vaccination
Introduction: One of the most significant current discussions in pediatrics is whether lumbar puncture (LP) should be performed in children with febrile seizure (FS) as in the past. Objectives: We compared the prevalence of meningitis among FS children before and after the pentavalent vaccine to determine the importance of the LP in these children.
Confronting Vaccine Production, Efficacy, Safety, and Accessibility Challenges in Africa
Vaccination is universally acknowledged as one of the most effective public health interventions. However, Africa faces unique challenges that impede the success of its vaccination programs. These challenges span from the biological aspects of vaccine development and production to the socio-economic and infrastructural barriers affecting vaccine distribution and acceptance. This commentary aims to provide a comprehensive overview of these issues and propose viable strategies for enhancing vaccination efforts across the continent.